Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.